Immunovant Inc is a clinical-stage biopharmaceutical company... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
IMVT is expected to report earnings to fall 6.32% to -71 cents per share on May 28
Q1'25
Est.
$-0.71
Q4'24
Missed
by $0.01
Q3'24
Missed
by $0.15
Q2'24
Est.
$-0.52
Q1'24
Missed
by $0.09
The last earnings report on February 06 showed earnings per share of -75 cents, missing the estimate of -75 cents. With 3.71M shares outstanding, the current market capitalization sits at 2.79B.